tbuckley/cabot-search huggingface dataset:
<i>Akkermansia muciniphila</i> supplementation prevents cognitive impairment in sleep-deprived mice by modulating microglial engulfment of synapses
Authors: Na Li, Shuwen Tan, Yue Wang, Jiao Deng, Nan Wang, Shan Zhu, Wen Tian, Jing Xu, Qiang Wang
Journal: Gut Microbes (2023)

The microbiome-gut-brain axis plays a crucial role in many neurological diseases, including mild cognitive impairment. Sleep deprivation (SD) induces cognitive decline accompanied by alterations in the gut microbiota. However, the role of gut microbiota alterations in SD-induced cognitive dysfunction and the underlying mechanisms remain unclear. Here, we found that dysbiosis of the gut microbiota following pretreatment with broad-spectrum antibiotics worsens SD-induced cognitive impairment in mice. Fecal microbiota transplantation from SD mice to healthy mice induced cognitive impairment. Additionally, the abundance of Akkermansia muciniphila (A. muciniphila) in the mouse gut microbiota was significantly reduced after 7 days of SD. A. muciniphila pretreatment alleviated cognitive dysfunction and prevented synaptic reduction in the hippocampus in SD mice. A. muciniphila pretreatment inhibited extensive microglial activation and synaptic engulfment in the hippocampus of SD mice. Metabolomics analysis revealed that A. muciniphila pretreatment increased the serum acetate and butanoic acid levels in SD mice. Finally, pretreatment with short-chain fatty acids (SCFAs) inhibited microglial synaptic engulfment and prevented neuronal synaptic loss in SD mice and primary microglia-neuron co-culture following LPS stimulation. Together, our findings illustrate that gut dysbiosis plays an essential role in SD-induced cognitive impairment by activating microglial engulfment at synapses. A. muciniphila supplementation may be a novel preventative strategy for SD-induced cognitive dysfunction, by increasing SCFAs production and maintaining microglial homeostasis.
Fibrin Stiffness Regulates Phenotypic Plasticity of Metastatic Breast Cancer Cells
Authors: Maria Heilala, Arttu Lehtonen, Ossi Arasalo, Aino Peura, Juho Pokki, Olli Ikkala, None Nonappa, Juha Klefström, Pauliina M. Munne
Journal: Advanced Healthcare Materials (2023)

The extracellular matrix (ECM)-regulated phenotypic plasticity is crucial for metastatic progression of triple negative breast cancer (TNBC). While ECM faithful cell-based models are available for in situ and invasive tumors, such as cell aggregate cultures in reconstituted basement membrane and in collagenous gels, there are no ECM faithful models for metastatic circulating tumor cells (CTCs). Such models are essential to represent the stage of metastasis where clinical relevance and therapeutic opportunities are significant. Here, CTC-like DU4475 TNBC cells are cultured in mechanically tunable 3D fibrin hydrogels. This is motivated, as in circulation fibrin aids CTC survival by forming a protective coating reducing shear stress and immune cell-mediated cytotoxicity and promotes several stages of late metastatic processes at the interface between circulation and tissue. This work shows that fibrin hydrogels support DU4475 cell growth, resulting in spheroid formation. Furthermore, increasing fibrin stiffness from 57 to 175 Pa leads to highly motile, actin and tubulin containing cellular protrusions, which are associated with specific cell morphology and gene expression patterns that markedly differ from basement membrane or suspension cultures. Thus, mechanically tunable fibrin gels reveal specific matrix-based regulation of TNBC cell phenotype and offer scaffolds for CTC-like cells with better mechano-biological properties than liquid.
Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment
Authors: Yaxin Du, Wenjie Wu, Mei Chen, Zhengbang Dong, Fei Wang
Journal: JAMA Dermatology (2023)

Growing research suggests that the prevalence of cutaneous immune-related adverse events (cirAEs) is associated with favorable outcomes among individuals with cancer who receive immune checkpoint inhibitor (ICI) treatment.
Many Young Contact Sport Players Had CTE on Autopsy
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Waiting for the changes after the adoption of steatotic liver disease
Authors: Eileen L. Yoon, Dae Won Jun
Journal: Clinical and Molecular Hepatology (2023)

Steatotic liver disease was suggested as an overarching term encompassing various etiologies of hepatic steatosis. Experts from multinational liver societies went through the Delphi process, including four rounds of surveys, and consented to adopt a new nomenclature and definition instead of the conventional nonalcoholic fatty liver disease (NAFLD). This was to improve the understanding of the patients and primary care physicians, with an explanation of the pathophysiology in the name of the disease. Also, it could minimize the stigmatization of patients by using the histological neutral term "steatosis" instead of "fatty". Herein, we will discuss the changes and continuity between the two nomenclatures, metabolic dysfunction-associated steatotic liver disease (MASLD) and NAFLD, as well as the challenges to MASLD which need to be addressed in future.
So Grateful for My X: Sex Chromosomes Drive Differences in Glioblastoma Immunity
Authors: Elise Alspach
Journal: Cancer Discovery (2023)

Males are at a greater risk of developing glioblastoma and face poorer prognoses compared with their female counterparts for reasons that are not well understood. Lee and colleagues uncover a role for sex-based differences in CD8+ T-cell function, which adds another layer to our growing understanding that antitumor immunity is not generated equivalently between males and females. See related article by Lee et al., p. 2090 (5).
Tailored Drug Delivery Platforms: Stimulus‐Responsive Core–Shell Structured Nanocarriers
Authors: Yulong Shi, Yiran Zhang, Liangliang Zhu, Yuqing Miao, Yueqi Zhu, Bingbing Yue
Journal: Advanced Healthcare Materials (2023)

Core-shell structured nanocarriers have come into the scientific spotlight in recent years due to their intriguing properties and wide applications in materials chemistry, biology, and biomedicine. Tailored core-shell structures to achieve desired performance have emerged as a research frontier in the development of smart drug delivery system. However, systematic reviews on the design and loading/release mechanisms of stimulus-responsive core-shell structured nanocarriers are uncommon. This review starts with the categories of core-shell structured nanocarriers with different means of drug payload, and then highlights the controlled release mechanism realized through stimulus-response processes triggered under different environments. Finally, some multifaceted perspectives on the design of core-shell structured materials as drug carriers are addressed. This work aims to provide new enlightenments and prospects in the drug delivery field for further developing advanced and smart nanocarriers.
Environmental Impact Assessment of Reusable and Disposable Surgical Head Covers
Authors: Eva S. Cohen, Sarah Djufri, Selma Bons, Mike. R. Knoppert, Wouter J. K. Hehenkamp, Lisanne H. J. A. Kouwenberg, Nicolaas H. Sperna Weiland
Journal: JAMA Surgery (2023)

This life cycle assessment compares the environmental footprint of reusable surgical head covers with single-use disposable surgical head covers.
Stress as a Risk Factor for Mental Disorders in a Gendered Environment
Authors: Carolyn M. Mazure, Mathilde M. Husky, Robert H. Pietrzak
Journal: JAMA Psychiatry (2023)

This Viewpoint discusses the value of assessing specific stressors that may vary by gender when assessing mental health to better inform our knowledge of stress effects and aid in developing better targeted, gender-informed prevention and treatment efforts in psychiatry.
Atopic dermatitis and risk for headache disorders and migraines: a population-based cohort study in children and adults from the UK
Authors: Zelma C Chiesa Fuxench, Joy Wan, Sonia Wang, Maha N Syed, Daniel B Shin, Katrina Abuabara, Joel M Gelfand
Journal: British Journal of Dermatology (2023)

Journal Article Accepted manuscript Atopic Dermatitis and risk for headache disorders and migraines: a population-based cohort study in children and adults from the United Kingdom Get access Zelma C Chiesa Fuxench, Zelma C Chiesa Fuxench Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA Corresponding author: Joel Gelfand, MD, MSCE, Email: joel.gelfand@pennmedicine.upenn.edu; Zelma C. Chiesa Fuxench, MD, MSCE, Email: zchi@pennmedicine.upenn.edu Search for other works by this author on: Oxford Academic Google Scholar Joy Wan, Joy Wan Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA https://orcid.org/0000-0002-0189-0442 Search for other works by this author on: Oxford Academic Google Scholar Sonia Wang, Sonia Wang Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA https://orcid.org/0000-0002-0369-7697 Search for other works by this author on: Oxford Academic Google Scholar Maha N Syed, Maha N Syed Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA Search for other works by this author on: Oxford Academic Google Scholar Daniel B Shin, Daniel B Shin Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA Search for other works by this author on: Oxford Academic Google Scholar Katrina Abuabara, Katrina Abuabara Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA Search for other works by this author on: Oxford Academic Google Scholar Joel M Gelfand Joel M Gelfand Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USADepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA Corresponding author: Joel Gelfand, MD, MSCE, Email: joel.gelfand@pennmedicine.upenn.edu; Zelma C. Chiesa Fuxench, MD, MSCE, Email: zchi@pennmedicine.upenn.edu Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljad325, https://doi.org/10.1093/bjd/ljad325 Published: 06 September 2023 Article history Received: 05 June 2023 Accepted: 04 September 2023 Published: 06 September 2023
HHS To Invest $1.4 Billion in New COVID-19 Vaccines, Therapies
Authors: Emily Harris
Journal: JAMA (2023)

HHS To Invest $1.4 Billion in New COVID-19 Vaccines, Therapies An infusion of more than $1.4 billion will support the development of new COVID-19 vaccines and therapies, the US Department of Health and Human Services (HHS) said in a statement.The investment is a part of Project NextGen, a more than $5 billion initiative to develop new "tools and technologies" against the virus.Among other actions, the current awards will support phase 2b clinical trials for vaccines that induce more durable protection and the development of a new monoclonal antibody.The drug candidate, from Regeneron, will likely enter clinical trials this fall, according to the HHS, while trials for novel vaccines could start as soon as this winter.-Emily
Comorbidities and clinical response to cardiac resynchronization therapy: Patient‐level meta‐analysis from eight clinical trials
Authors: Marat Fudim, Frederik Dalgaard, Daniel J. Friedman, William T. Abraham, John G.F. Cleland, Anne B. Curtis, Michael R. Gold, Valentina Kutyifa, Cecilia Linde, Fatima Ali‐Ahmed, Anthony Tang, Antonio Olivas‐Martinez, Lurdes Y.T. Inoue, Sana M. Al‐Khatib, Gillian D. Sanders
Journal: European Journal of Heart Failure (2023)
Challenges and Opportunities in Building a Global Representative Single-Cell and Spatial Atlas in Cancer
Authors: Jasmine T. Plummer, Sophia H.L. George
Journal: Cancer Discovery (2023)

Summary: Cancer health disparities are complex and a mixture of factors that need to be accounted for in both our planning, implementation, and execution across all researchers, especially in single-cell and spatial technologies, which have a higher burden for adoption in low- and middle-income countries. This commentary tackles the hurdles these technologies face in creating a diverse, representative atlas of cancer and is a call to arms for a strategic plan toward inclusivity across all global populations.
Linking Kidney Vessel Scarring to Cardiovascular Risk
Authors: Thibaut d’Izarny-Gargas, Alexandre Karras, Jean-Paul Duong-Van-Huyen
Journal: JAMA Cardiology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
A Tribute to William C. Roberts, MD, 1932-2023
Authors: Clyde W. Yancy, Patrick T. O’Gara, Robert O. Bonow
Journal: JAMA Cardiology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
3D Volumetric Mechanosensation of MCF7 Breast Cancer Spheroids in a Linear Stiffness Gradient GelAGE
Authors: Danielle Vahala, Sebastian E. Amos, Marta Sacchi, Bram G. Soliman, Matt S. Hepburn, Alireza Mowla, Jiayue Li, Ji Hoon Jeong, Chrissie Astell, Yongsung Hwang, Brendan F. Kennedy, Khoon S. Lim, Yu Suk Choi
Journal: Advanced Healthcare Materials (2023)

Abstract The tumor microenvironment presents spatiotemporal shifts in biomechanical properties with cancer progression. Hydrogel biomaterials like GelAGE offer the stiffness tuneability to recapitulate dynamic changes in tumor tissues by altering photo‐energy exposures. Here, a tuneable hydrogel with spatiotemporal control of stiffness and mesh‐network is developed. The volume of MCF7 spheroids encapsulated in a linear stiffness gradient demonstrates an inverse relationship with stiffness ( p &lt; 0.0001). As spheroids are exposed to increased crosslinking (stiffer) and greater mechanical confinement, spheroid stiffness increases. Protein expression (TRPV4, β1 integrin, E‐cadherin, and F‐actin) decreases with increasing stiffness while showing strong correlations to spheroid volume ( r 2 &gt; 0.9). To further investigate the role of volume, MCF7 spheroids are grown in a soft matrix for 5 days prior to a second polymerisation which presents a stiffness gradient to equally expanded spheroids. Despite being exposed to variable stiffness, these spheroids show even protein expression, confirming volume as a key regulator. Overall, this work showcases the versatility of GelAGE and demonstrates volume expansion as a key regulator of 3D mechanosensation in MCF7 breast cancer spheroids. This platform has the potential to further investigation into the role of stiffness and dimensionality in 3D spheroid culture for other types of cancers and diseases.
Antidepressant Use and Mortality Among Patients With Hepatocellular Carcinoma
Authors: Kuan-Lun Huang, Yi-Lung Chen, Robert Stewart, Vincent Chin-Hung Chen
Journal: JAMA Network Open (2023)

Liver cancer, primarily hepatocellular carcinoma (HCC), is the third leading cause of cancer deaths worldwide. Although some studies have proposed that antidepressants may have apoptotic effects on cancer, no study has examined the association between antidepressant use and HCC prognosis.To investigate the association between antidepressant use and mortality risk in patients with HCC.This population-based cohort study analyzed Taiwan's National Health Insurance Research Database, which covers 99% of Taiwan's population and includes comprehensive medical information. Patients with a new diagnosis of HCC between 1999 and 2017 were identified. Analysis took place in June 2023.All patients with HCC were followed up until 2018 to measure overall and cancer-specific mortality. To examine whether the timing of antidepressant use influenced the association with mortality, antidepressant use was examined before and after HCC diagnosis. Cox proportional hazards regression was performed to estimate hazard ratios (HRs) and the 95% CIs for the association between antidepressant use and overall mortality and cancer-specific mortality.The study cohort comprised 308 938 participants, primarily consisting of older individuals (131 991 [42.7%] were aged ≥65 years) with a higher proportion of male individuals (202 589 [65.6%]). Antidepressant use before the diagnosis of HCC was not associated with lower risks of overall mortality (adjusted HR, 1.10; 95% CI, 1.08-1.12) and cancer-specific mortality (adjusted HR, 1.06; 95% CI, 0.96-1.17). However, antidepressant use after a diagnosis of HCC was associated with a lower risk of overall mortality (adjusted HR, 0.69; 95% CI, 0.68-0.70) and cancer-specific mortality (adjusted HR, 0.63; 95% CI, 0.59-0.68). The observed associations were consistent across subgroups with different antidepressant classes and comorbidities, including hepatitis B virus or hepatitis C virus infection, liver cirrhosis, and alcohol use disorders.Based on this nationwide cohort study, postdiagnosis antidepressant use may be associated with lower mortality in patients with HCC. Further randomized clinical trial evaluation should be considered.
Acquired Melanocytic Nevi Mimicking Acral Lentiginous Melanoma in a Patient Taking a BRAF Inhibitor
Authors: Zaeem H. Nazir, Helen C. Haliasos, Klaus J. Busam, Michael A. Marchetti, Konstantinos Linos, Ashfaq A. Marghoob
Journal: JAMA Dermatology (2023)

This case report describes a patient in their 60s with metastatic colon cancer who developed multiple new dark nevi within 2 months of initiating encorafenib and panitumumab therapy.
A novel missense variant in <scp><i>ATP11C</i></scp> is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia
Authors: Myrthe J. van Dijk, Brigitte A. van Oirschot, Alexander N. Harrison, Steffen M. Recktenwald, Min Qiao, Amaury Stommen, Anne‐Sophie Cloos, Juliette Vanderroost, Romano Terrasi, Kuntal Dey, Jennifer Bos, Minke A. E. Rab, Anna Bogdanova, Giampaolo Minetti, Giulio G. Muccioli, Donatienne Tyteca, Stéphane Egée, Lars Kaestner, Robert S. Molday, Eduard J. van Beers, Richard van Wijk
Journal: American Journal of Hematology (2023)

Abstract Adenosine Triphosphatase (ATPase) Phospholipid Transporting 11C gene (ATP11C) encodes the major phosphatidylserine (PS) flippase in human red blood cells (RBCs). Flippases actively transport phospholipids (e.g., PS) from the outer to the inner leaflet to establish and maintain phospholipid asymmetry of the lipid bilayer of cell membranes. This asymmetry is crucial for survival since externalized PS triggers phagocytosis by splenic macrophages. Here we report on pathophysiological consequences of decreased flippase activity, prompted by a patient with hemolytic anemia and hemizygosity for a novel c.2365C &gt; T p.(Leu789Phe) missense variant in ATP11C . ATP11C protein expression was strongly reduced by 58% in patient‐derived RBC ghosts. Furthermore, functional characterization showed only 26% PS flippase activity. These results were confirmed by recombinant mutant ATP11C protein expression in HEK293T cells, which was decreased to 27% compared to wild type, whereas PS‐stimulated ATPase activity was decreased by 57%. Patient RBCs showed a mild increase in PS surface exposure when compared to control RBCs, which further increased in the most dense RBCs after RBC storage stress. The increase in PS was not due to higher global membrane content of PS or other phospholipids. In contrast, membrane lipid lateral distribution showed increased abundance of cholesterol‐enriched domains in RBC low curvature areas. Finally, more dense RBCs and subtle changes in RBC morphology under flow hint toward alterations in flow behavior of ATP11C‐deficient RBCs. Altogether, ATP11C deficiency is the likely cause of hemolytic anemia in our patient, thereby underlining the physiological role and relevance of this flippase in human RBCs.
Procurement of Pancreatic Tissue for Research From Deceased Donors Before vs After the CMS Final Rule in 2020
Authors: David S. Goldberg, Darren D. Lahrman, Matthew Wadsworth
Journal: JAMA Network Open (2023)

This cohort study examines changes in research pancreas procurement from deceased donors before and after the Centers for Medicare & Medicaid Services (CMS) updated its Final Rule in November 2020.